Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Corvus: Q1 Earnings Snapshot

Corvus: Q1 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus: Q4 Earnings Snapshot

Corvus: Q4 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus: Q3 Earnings Snapshot

Corvus: Q3 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus: Q2 Earnings Snapshot

Corvus: Q2 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus: Q1 Earnings Snapshot

Corvus: Q1 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus: Q4 Earnings Snapshot

Corvus: Q4 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus: Q3 Earnings Snapshot

Corvus: Q3 Earnings Snapshot

CRVS : 1.8200 (+2.25%)
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Prioritizing Development of CPI-818 for T Cell Lymphomas, Autoimmune and Allergic Diseases Plans to Begin Phase 2 Clinical Trial of Ciforadenant in...

CRVS : 1.8200 (+2.25%)
Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage...

CRVS : 1.8200 (+2.25%)
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical...

CRVS : 1.8200 (+2.25%)

Barchart Exclusives

These 3 High-yielding Dividend Aristocrats Are Also Up 10% YTD
On the hunt for quality companies with positive price performance? These 3 are up 10% YTD and offer above-average yields. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar